Lars Bastholt
Odense University Hospital · 332 works · 32,534 citations · h-index 62
Top works
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
- A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline
- Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
- AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
- Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model
- Osteoradionecrosis of the jaws: Clinical characteristics and relation to the field of irradiation
- Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer